Publications by authors named "Gary Calandra"

Claim this Profile
A
Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210.
Victoria A Johnson, Yoninah S Cramer, Susan L Rosenkranz, Stephen Becker, Karin L Klingman, Gary Calandra

AIDS Res Hum Retroviruses· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of high-dose plerixafor on CD34 cell mobilization in healthy stem cell donors: results of a randomized crossover trial.
Jeremy Pantin, Enkhtsetseg Purev, Xin Tian, Lisa Cook, Theresa Donohue-Jerussi, Gary Calandra

Haematologica· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF.
Andreas Lundqvist, Aleah L Smith, Yoshiyuki Takahashi, Susan Wong, Erkut Bahceci, Gary Calandra

J Immunol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.
Richard T Maziarz, Auayporn P Nademanee, Ivana N Micallef, Patrick J Stiff, Gary Calandra

Biol Blood Marrow Transplant· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma.
Jonathan L Kaufman, Christopher R Flowers, Karen D Rados, Gary B Calandra, Julie M Vose

Transfusion· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers.
Steven J Lemery, Matthew M Hsieh, Aleah Smith, Sheila Rao, Hanh M Khuu, Gary Calandra

Br J Haematol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CXCR4 in clinical hematology.
Gary Calandra, Gary Bridger, Simon Fricker

Curr Top Microbiol Immunol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.
Neal Flomenberg, Raymond L Comenzo, Karin Badel, Gary Calandra

Biol Blood Marrow Transplant· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment.
Ronald MacFarland, Marjie L Hard, Robert Scarborough, Karin Badel, Gary Calandra

Biol Blood Marrow Transplant· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study.
Stefan Fruehauf, Marlon Romano Veldwijk, Timon Seeger, Mario Schubert, Stephanie Laufs, Gary Calandra

Cytotherapy· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted antagonism of CXCR4 mobilizes progenitor cells under investigation for cardiovascular disease.
Arnon Blum, Richard W Childs, Aleah Smith, Sushmitha Patibandla, Gloria Zalos, Gary Calandra

Cytotherapy· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.
Ivana N Micallef, Patrick J Stiff, John F DiPersio, Richard T Maziarz, John M McCarty, Gary Calandra

Biol Blood Marrow Transplant· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.
Falk Dillmann, Marlon R Veldwijk, Stephanie Laufs, Markus Sperandio, Gary Calandra

Leuk Lymphoma· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.
John F DiPersio, Ivana N Micallef, Patrick J Stiff, Brian J Bolwell, Richard T Maziarz, Gary Calandra

J Clin Oncol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.
John F DiPersio, Edward A Stadtmauer, Auayporn Nademanee, Ivana N M Micallef, Patrick J Stiff, Gary Calandra

Blood· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1.
Graeme Moyle, Edwin DeJesus, Marta Boffito, Rebecca S Wong, Colleen Gibney, Gary Calandra

Clin Infect Dis· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
Patrick Stiff, Ivana Micallef, Philip McCarthy, Margarida Magalhaes-Silverman, Daniel Weisdorf, Gary Calandra

Biol Blood Marrow Transplant· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
Douglas A Stewart, Clayton Smith, Ron MacFarland, Gary Calandra

Biol Blood Marrow Transplant· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.
Amanda Cashen, Sandra Lopez, Feng Gao, Gary Calandra, Ron MacFarland

Biol Blood Marrow Transplant· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction.
Steven M Devine, Ravi Vij, Michael Rettig, Laura Todt, Kiley McGlauchlen, Gary Calandra

Blood· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers.
Myaing M Nyunt, Stephen Becker, Ron T MacFarland, Priscilla Chee, Robert Scarborough, Gary B Calandra

J Acquir Immune Defic Syndr· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilisation with G-CSF plus AMD3100 in patients with multiple myeloma.
Uta Oelschlaegel, Martin Bornhauser, Sabine Boxberger, Frank Kroschinsky, Thomas Illmer, Gary Calandra

Ann Hematol· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients.
Yair Gazitt, Cesar O Freytes, Cagla Akay, Karin Badel, Gary Calandra

Stem Cells Dev· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects.
Nimalie D Stone, Shelia B Dunaway, Charles Flexner, Camlin Tierney, Gary B Calandra

Antimicrob Agents Chemother· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 Antagonist.
Kai Hübel, W Conrad Liles, Hal E Broxmeyer, Elin Rodger, Brent Wood, Gary Calandra

Support Cancer Ther· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis